GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (LTS:0R1F) » Definitions » Total Equity

Bristol-Myers Squibb Co (LTS:0R1F) Total Equity : $16,548 Mil (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Bristol-Myers Squibb Co Total Equity?

Bristol-Myers Squibb Co's total equity for the quarter that ended in Mar. 2024 was $16,548 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Bristol-Myers Squibb Co Total Equity Historical Data

The historical data trend for Bristol-Myers Squibb Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Total Equity Chart

Bristol-Myers Squibb Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 51,698.00 37,882.00 36,006.00 31,118.00 29,485.00

Bristol-Myers Squibb Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31,886.00 32,030.00 29,062.00 29,485.00 16,548.00

Bristol-Myers Squibb Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Bristol-Myers Squibb Co's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity=Total Assets(Q: Dec. 2023 )-Total Liabilities(Q: Dec. 2023 )
=95159-65674
=29,485

Bristol-Myers Squibb Co's Total Equity for the quarter that ended in Mar. 2024 is calculated as

Total Equity=Total Assets(Q: Mar. 2024 )-Total Liabilities(Q: Mar. 2024 )
=99031-82483
=16,548

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bristol-Myers Squibb Co Total Equity Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bristol-Myers Squibb Co (LTS:0R1F) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bristol-Myers Squibb Co (LTS:0R1F) » Definitions » Total Equity
Comparable Companies
GILD PFE AMGN BIIB OGN AMRN SCLX MIRA ABBV MRK LLY JNJ LSE:AZN XSWX:NOVN XSWX:ROG XPAR:SAN LSE:GSK TSE:4568 TSE:4519 SHSE:600276
Traded in Other Exchanges
BMYMP.PFD:USA BMY:USA BMY:Peru BMY:Mexico 1BMY:Italy BRMd:UK BRM:Germany BMYB34:Brazil BMYS:Austria BMY:Argentina
Address
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Website
https://www.bms.com
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the U.S., showing a higher dependence on the U.S. market than most of its peer group.

Bristol-Myers Squibb Co (LTS:0R1F) Headlines

No Headlines